+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using FCER1A mouse mAb against SW620 (1), A549 (2), and A431 (3) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of HEK293 cells using FCER1A mouse mAb (green) and negative control (red).    

  
  

FCER1A encodes the alpha subunit of the high-affinity immunoglobulin E (IgE) receptor (FcεRI), a critical player in allergic and inflammatory responses. As a multi-chain receptor, FcεRI consists of an alpha chain (FCER1A), a beta chain, and two gamma chains. The alpha subunit specifically binds the Fc region of IgE antibodies, anchoring them to the surface of mast cells and basophils. Upon allergen exposure, cross-linking of IgE-loaded FcεRI triggers cell degranulation, releasing histamine, cytokines, and other mediators that drive immediate hypersensitivity reactions (e.g., anaphylaxis) and chronic allergic inflammation.

FCER1A antibodies are essential tools for studying receptor expression, signaling mechanisms, and IgE-mediated immune regulation. They are widely used in flow cytometry, immunohistochemistry, and Western blotting to quantify FcεRI levels on immune cells, particularly in research on asthma, atopic dermatitis, and food allergies. Clinically, elevated FcεRI expression correlates with disease severity in allergic disorders, making FCER1A a potential biomarker. Additionally, therapeutic strategies targeting FcεRI-IgE interactions, such as monoclonal antibodies (e.g., omalizumab), leverage insights from FCER1A biology to dampen allergic responses. Genetic variants in FCER1A have also been linked to altered IgE levels and susceptibility to allergies, highlighting its role in immune dysregulation. Overall, FCER1A antibodies bridge basic research and clinical applications, offering insights into allergic pathogenesis and therapeutic development.